Abstract Kawasaki disease is an acute, self-limited vascuitis that mainly occurs in children under 5 years of age. Intravenous immunoglobulin (IVIG) has become an effective treatment regimen, which can effectively reduce the incidence of cardiovascular complications. However, there has been no consensus or clinical guidelines for the application of IVIG in children with Kawasaki disease till now. This consensus is developed based on the current research progress on the application of IVIG in children with Kawasaki disease in China and overseas, with reference to the diagnosis and treatment guidelines for Kawasaki disease in China and overseas, and the opinions of experts. This consensus provides recommendations on the clinical application strategy of IVIG in children with Kawasaki disease and the prevention and treatment of its adverse reactions. Citation:
Ae R, Makino N, Kosami K, et al. Epidemiology, treatments, and cardiac complications in patients with Kawasaki disease: the nationwide survey in Japan, 2017-2018[J]. J Pediatr, 2020, 225: 23-29.e2. PMID: 32454114. DOI: 10.1016/j.jpeds.2020.05.034.
Barrios Tascón A, Centeno Malfaz F, Rojo Sombrero H, et al. National consensus on the cardiological treatment and follow-up of Kawasaki disease[J]. An Pediatr (Barc), 2018, 89(3): 188.e1-188.e22. PMID: 29778491. DOI: 10.1016/j.anpedi.2018.04.003.
McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association[J]. Circulation, 2017, 135(17): e927-e999. PMID: 28356445. DOI: 10.1161/CIR.0000000000000484.
Fukazawa R, Kobayashi J, Ayusawa M, et al. JCS/JSCS 2020 guideline on diagnosis and management of cardiovascular sequelae in Kawasaki disease[J]. Circ J, 2020, 84(8): 1348-1407. PMID: 32641591. DOI: 10.1253/circj.CJ-19-1094.
Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association[J]. Circulation, 2004, 110(17): 2747-2771. PMID: 15505111. DOI: 10.1161/01.CIR.0000145143.19711.78.
Miyata K, Miura M, Kaneko T, et al. Risk factors of coronary artery abnormalities and resistance to intravenous immunoglobulin plus corticosteroid therapy in severe Kawasaki disease: an analysis of post RAISE[J]. Circ Cardiovasc Qual Outcomes, 2021, 14(2): e007191. PMID: 33541111. DOI: 10.1161/CIRCOUTCOMES.120.007191.
10 Suzuki T, Michihata N, Aso S, et al. Sodium-containing versus sodium-trace preparations of IVIG for children with Kawasaki disease in the acute phase[J]. Eur J Pediatr, 2021. PMID: 33973071. DOI: 10.1007/s00431-021-04096-x. Epub ahead of print.
Shimoni Z, Bulvik S, Froom P. Intravenous immune globulin in autoimmune and inflammatory diseases[J]. N Engl J Med, 2013, 368(8): 776-777. PMID: 23425182. DOI: 10.1056/NEJMc1215489.
Imbach P, Barandun S, Baumgartner C, et al. High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood[J]. Helv Paediatr Acta, 1981, 36(1): 81-86. PMID: 6785258.
Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin[J]. N Engl J Med, 1986, 315(6): 341-347. PMID: 2426590. DOI: 10.1056/NEJM198608073150601.
Teeling JL, Jansen-Hendriks T, Kuijpers TW, et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia[J]. Blood, 2001, 98(4): 1095-1099. PMID: 11493456. DOI: 10.1182/blood.v98.4.1095.
Guo MMH, Tseng WN, Ko CH, et al. Th17- and Treg-related cytokine and mRNA expression are associated with acute and resolving Kawasaki disease[J]. Allergy, 2015, 70(3): 310-318. PMID: 25585854. DOI: 10.1111/all.12558.
Rasouli M, Heidari B, Kalani M. Downregulation of Th17 cells and the related cytokines with treatment in Kawasaki disease[J]. Immunol Lett, 2014, 162(1 Pt A): 269-275. PMID: 25277751. DOI: 10.1016/j.imlet.2014.09.017.
Tajima M, Shiozawa Y, Kagawa J. Early appearance of principal symptoms of Kawasaki disease is a risk factor for intravenous immunoglobulin resistance[J]. Pediatr Cardiol, 2015, 36(6): 1159-1165. PMID: 25753685. DOI: 10.1007/s00246-015-1136-2.
Lin MC, Lai MS, Jan SL, et al. Epidemiologic features of Kawasaki disease in acute stages in Taiwan, 1997-2010: effect of different case definitions in claims data analysis[J]. J Chin Med Assoc, 2015, 78(2): 121-126. PMID: 25636582. PMCID: PMC7105041. DOI: 10.1016/j.jcma.2014.03.009.
Muta H, Ishii M, Yashiro M, et al. Late intravenous immunoglobulin treatment in patients with Kawasaki disease[J]. Pediatrics, 2012, 129(2): e291-e297. PMID: 22250032. DOI: 10.1542/peds.2011-1704.
Kuwabara M, Yashiro M, Ae R, et al.The effects of early intravenous immunoglobulin therapy for Kawasaki disease: the 22nd nationwide survey in Japan[J]. Int J Cardiol, 2018, 269(10): 334-338. PMID: 30049499. DOI: 10.1016/j.ijcard.2018.07.092.
Marchesi A, Tarissi de Jacobis I, Rigante D, et al. Kawasaki disease: guidelines of the Italian Society of Pediatrics, part I - definition, epidemiology, etiopathogenesis, clinical expression and management of the acute phase[J]. Ital J Pediatr, 2018, 44(1): 102. PMID: 30157897. PMCID: PMC6116535. DOI: 10.1186/s13052-018-0536-3.
Gamez-Gonzalez LB, Moribe-Quintero I, Cisneros-Castolo M, et al. Kawasaki disease shock syndrome: unique and severe subtype of Kawasaki disease[J]. Pediatr Int, 2018, 60(9): 781-790. PMID: 29888440. DOI: 10.1111/ped.13614.
31 Miura M, Ayusawa M, Fukazawa R, et al. Guidelines for medical treatment of acute Kawasaki disease (2020 revised version)[J]. J Pediatr Cardiol Card Surg, 2021, 5(1): 41-73. DOI: 10.24509/jpccs.0501G1.
32 Zhu F, Ang JY. 2021 update on the clinical management and diagnosis of Kawasaki disease[J]. Curr Infect Dis Rep, 2021, 23(3): 3. DOI: 10.1007/s11908-021-00746-1.
Durongpisitkul K, Gururaj VJ, Park JM, et al. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment[J]. Pediatrics, 1995, 96(6): 1057-1061. PMID: 7491221.
Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose[J]. J Pediatr, 1997, 131(6): 888-893. PMID: 9427895. DOI: 10.1016/s0022-3476(97)70038-6.
Sawaji Y, Haneda N, Yamaguchi S, et al. Coronary risk factors in acute Kawasaki disease: correlation of serum immunoglobulin levels with coronary complications[J]. Acta Paediatr Jpn, 1998, 40(3): 218-225. PMID: 9695293. DOI: 10.1111/j.1442-200x.1998.tb01915.x.
Dajani AS, Taubert KA, Gerber MA, et al. Diagnosis and therapy of Kawasaki disease in children[J]. Circulation, 1993, 87(5): 1776-1780. PMID: 8491037. DOI: 10.1161/01.cir.87.5.1776.
Cherin P, Marie I, Michallet M, et al. Management of adverse events in the treatment of patients with immunoglobulin therapy: a review of evidence[J]. Autoimmun Rev, 2016, 15(1): 71-81. PMID: 26384525. DOI: 10.1016/j.autrev.2015.09.002.
Finkel AG, Howard JFJ, Mann JD. Successful treatment of headache related to intravenous immunoglobulin with antimigraine medications[J]. Headache, 1998, 38(4): 317-321. PMID: 9595875. DOI: 10.1046/j.1526-4610.1998.3804317.x.
Abolhassani H, Asgardoon MH, Rezaei N, et al. Different brands of intravenous immunoglobulin for primary immunodeficiencies: how to choose the best option for the patient?[J]. Expert Rev Clin Immunol, 2015, 11(11): 1229-1243. PMID: 26289377. DOI: 10.1586/1744666X.2015.1079485.
Ramírez E, Romero-Garrido JA, López-Granados E, et al. Symptomatic thromboembolic events in patients treated with intravenous-immunoglobulins: results from a retrospective cohort study[J]. Thromb Res, 2014, 133(6): 1045-1051. PMID: 24731561. DOI: 10.1016/j.thromres.2014.03.046.
Liu E, Gonzalez J, Siu A. Use of premedication with intravenous immune globulin in Kawasaki disease: a retrospective review[J]. Pediatr Allergy Immunol, 2021, 32(4): 750-755. PMID: 33326647. DOI: 10.1111/pai.13432.
Matsuda M, Hosoda W, Sekijima Y, et al. Neutropenia as a complication of high-dose intravenous immunoglobulin therapy in adult patients with neuroimmunologic disorders[J]. Clin Neuropharmacol, 2003, 26(6): 306-311. PMID: 14646610. DOI: 10.1097/00002826-200311000-00009.
Jiao FY, Yan XH, Wu XF. The Xi'an experience of Kawasaki disease: lessons learnt over 5 years[J]. Indian J Pediatr, 2016, 83(10): 1195-1196. PMID: 27094776. DOI: 10.1007/s12098-016-2100-8.
Singh S, Sharma A, Jiao FY. Kawasaki disease: issues in diagnosis and treatment--a developing country perspective[J]. Indian J Pediatr, 2016, 83(2): 140-145. PMID: 26400032. DOI: 10.1007/s12098-015-1890-4.
McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association[J]. Circulation, 2017, 135(17): e927-e999. PMID: 28356445. DOI: 10.1161/CIR.0000000000000484.
Soni PR, Noval Rivas M, Arditi M. A comprehensive update on Kawasaki disease vasculitis and myocarditis[J]. Curr Rheumatol Rep, 2020, 22(2): 6. PMID: 32020498. DOI: 10.1007/s11926-020-0882-1.
Samadli S, Liu FF, Mammadov G, et al. The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease[J]. Pediatr Rheumatol Online J, 2019, 17(1): 53. PMID: 31366406. PMCID: PMC6668082. DOI: 10.1186/s12969-019-0352-3.
Ferreira D, Ng R, Lai E, et al. Kawasaki disease in the Australian population: an Australian tertiary hospital experience[J]. Heart Lung Circ, 2021, 30(7): 996-1001. PMID: 33612428. DOI: 10.1016/j.hlc.2020.12.016.
Vervoort D, Donné M, Van Gysel D. Pitfalls in the diagnosis and management of Kawasaki disease: an update for the pediatric dermatologist[J]. Pediatr Dermatol, 2018, 35(6): 743-747. PMID: 30338568. DOI: 10.1111/pde.13620.
Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease[J]. Circulation, 2006, 113(22): 2606-2612. PMID: 16735679. DOI: 10.1161/CIRCULATIONAHA.105.592865.
Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease[J]. J Pediatr, 2006, 149(2): 237-240. PMID: 16887442. DOI: 10.1016/j.jpeds.2006.03.050.
Sano T, Kurotobi S, Matsuzaki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment[J]. Eur J Pediatr, 2007, 166(2): 131-137. PMID: 16896641. DOI: 10.1007/s00431-006-0223-z.
WANG Hui-Min, LIU Chuan-He, LIU Chang-Shan, WANG Ying, HAN Zhi-Ying, SUN Xin, CHEN Xing, AN Shu-Hua, DUOLIKUN Muzhapaer, LU Ai-Ping, WANG Min, CHENG Yan, YIN Xiao-Mei, LIU Han-Min, WANG Hong, HUA Shan, DONG Li, HUANG Ying, JIANG Yi, XIONG Jian-Xin, DING Sheng-Gang, ZHAO Shun-Ying, WANG Jin-Rong, HUANG Gui-Min, MU Jing-Hui, CHEN Yu-Zhi. Efficacy of Huaiqihuang granules as adjuvant therapy for bronchial asthma in children: a real-world study[J]. CJCP, 2021, 23(9): 877-881.